Source: Eur Respir J 2002; 20: 588-596
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Bateman E.D., Frith L.F., Braunstein G.L.. Achieving guideline-based asthma control: does the patient benefit?. Eur Respir J 2002; 20: 588-596

Member's Comments

No comment yet.

Related content which might interest you: Is overall asthma control being achieved? A hypothesis-generating study Source: Eur Respir J 2001; 17: 589-595 Year: 2001 The correlation between asthma control and health status: the GOAL study Source: Eur Respir J 2007; 29: 56-62 Year: 2007 Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial Source: Eur Respir J 2003; 22: 787-794 Year: 2003 High or standard initial dose of budesonide to control mild-to-moderate asthma? Source: Eur Respir J 2001; 17: 856-862 Year: 2001 Health care resource utilization following addition of montelukast or salmeterol to fluticasone in patients with inadequately controlled asthma (IMPACT trial) Source: Eur Respir J 2004; 24: Suppl. 48, 127s Year: 2004 Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease Source: Eur Respir J 2003 Dec 01;22(6):912-919 Year: 2003 Suboptimal asthma control in patients receiving long-term maintenance therapy Source: Annual Congress 2006 - The challenges of managing asthma in primary care Year: 2006 Assessment of the bioequivalence of two DPIs containing fluticasone and salmeterol, in patients with controlled or partly controlled asthma Source: International Congress 2016 – Clinical characteristics of asthma Year: 2016 Survival in COPD patients after regular use of salmeterol and/or fluticasone propionate in general practice Source: Eur Respir J 2001; 18: Suppl. 33, 348s Year: 2001 Achievement of total control of asthma in clinical practice using the combination of inhaled salmeterol and fluticasone propionate Source: Eur Respir J 2006; 28: Suppl. 50, 616s Year: 2006 Comparative efficacy and costs of the treatment of moderate to severe persistent asthma with a new dry-powder inhaled beclomethasone dipropionate and formoterol combination Source: Annual Congress 2013 –Health economics of airway diseases Year: 2013 Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma Source: Eur Respir J 2008; 31: 982-989 Year: 2008 Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function Source: Eur Respir J 2012; 39: 279-289 Year: 2012 Health related quality of life evaluation after beclomethasone dipropionate (BDP) treatment in children with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 381s Year: 2004 Tiotropium + olodaterol provides significant lung-function benefits compared to fluticasone + salmeterol regardless of prior bronchodilator use Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Impact of adherence to fluticasone propionate/salmeterol combination (FSC) therapy on the outcomes of patients with asthma: A population based study Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013 Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Improved asthma control with budesonide/formoterol via a single inhaler, compared with budesonide alone, in moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 48s Year: 2001